MacroGenics (MGNX)- Jon Marc Wigginton, Sr. VP Clinical Development & CMO, sold 5,000 shares at $27.22. Wigginton does not own any shares of MGNX. Lynn Cilinski, VP, Controller and Treasurer, sold 8,922 shares at $27.22. Cilinski still owns 1,923 shares of MGNX.
Egalet (EGLT)- Robert S. Radie, President & CEO, sold 15,000 shares in three separate transactions. Radie sold 5,000 shares at $5.07; 5,000 shares at $4.94; and 5,000 shares at $5.02. Radie still owns 249,900 shares of EGLT. Stan Musial, CFO, sold 13,480 shares in two separate transactions. Musial sold 10,000 shares at $5.06; and 3,480 shares at $5.05. Musial still owns 81,460 shares of EGLT.
Acceleron Pharma (XLRN)- Matthew L. Sherman, EVP & Chief Medical Officer, sold 26,000 shares at $34.74. Sherman still owns 73,604 shares of XLRN. Steven D. Ertel, EVP & Chief Operating Officer, sold 32,270 shares in two separate transactions. Ertel sold 28,304 shares at $34.77; and 3,966 shares at $33.05. Ertel still owns 127,156 shares of XLRN. Kevin F. McLaughlin, SVP, CFO and Treasurer, sold 25,300 shares at $34.66. McLaughlin still owns 57,600 shares of XLRN. John L. Knopf, CEO and President, sold 100,000 shares in three separate transactions. Knopf still owns 119,084 shares of XLRN.
Alkermes (ALKS)- Paul J. Mitchell, Director, sold 2,000 shares at $45.81. The total value of the transaction was $91,620. Mitchell still owns 8,000 shares of ALKS.
Ophthotech (OPHT)- David R. Guyer, CEO, sold 24,060 shares at $52.12. The total value of the transaction was approximately $1.25 million. Guyer still owns 32,391 shares of OPHT.